Dashboard
1
Poor Management Efficiency with a low ROCE of 4.33%
- The company has been able to generate a Return on Capital Employed (avg) of 4.33% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -7.46% and Operating profit at -11.85% over the last 5 years
3
Flat results in Mar 25
4
With ROE of 4.26%, it has a very expensive valuation with a 3.51 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,651 Million (Mid Cap)
82.00
NA
0.18%
0.23
4.26%
3.51
Revenue and Profits:
Net Sales:
163 Million
(Quarterly Results - Jun 2025)
Net Profit:
14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.79%
0%
-23.79%
6 Months
73.01%
0%
73.01%
1 Year
130.55%
0%
130.55%
2 Years
95.78%
0%
95.78%
3 Years
82.28%
0%
82.28%
4 Years
198.36%
0%
198.36%
5 Years
106.73%
0%
106.73%
Nanjing Hicin Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-7.46%
EBIT Growth (5y)
-11.85%
EBIT to Interest (avg)
5.66
Debt to EBITDA (avg)
1.66
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
0.39
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
29.83%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.33%
ROE (avg)
4.12%
Valuation key factors
Factor
Value
P/E Ratio
82
Industry P/E
Price to Book Value
3.51
EV to EBIT
74.06
EV to EBITDA
36.01
EV to Capital Employed
3.04
EV to Sales
6.89
PEG Ratio
12.50
Dividend Yield
0.18%
ROCE (Latest)
4.11%
ROE (Latest)
4.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
162.50
139.50
16.49%
Operating Profit (PBDIT) excl Other Income
31.80
32.10
-0.93%
Interest
1.80
1.80
Exceptional Items
0.00
0.00
Consolidate Net Profit
13.90
15.00
-7.33%
Operating Profit Margin (Excl OI)
107.60%
127.30%
-1.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 16.49% vs -1.20% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -7.33% vs 25.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
493.70
506.50
-2.53%
Operating Profit (PBDIT) excl Other Income
96.00
97.00
-1.03%
Interest
9.20
8.30
10.84%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
40.20
36.30
10.74%
Operating Profit Margin (Excl OI)
100.80%
85.80%
1.50%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.53% vs -1.97% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 10.74% vs 13.08% in Dec 2023
About Nanjing Hicin Pharmaceutical Co., Ltd. 
Nanjing Hicin Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






